<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894539</url>
  </required_header>
  <id_info>
    <org_study_id>20190821</org_study_id>
    <nct_id>NCT04894539</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Nerve Stimulation for Labor Pain Control</brief_title>
  <official_title>Transcutaneous Electrical Nerve Stimulation as a Pain-relieving Approach in Labor Pain Control: a Randomized Double-blinded Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centaflow</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herning Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcutaneous electrical nerve stimulation (TENS) is a non-invasive electro-physical&#xD;
      modality used for several pain conditions including labor pain control. Despite several years&#xD;
      of research, there is still no agreement within the literature regarding the selection of&#xD;
      TENS parameters. It is aimed to investigate two types of TENS frequencies (TENS1 alternating&#xD;
      between 4 to 100 Hz and TENS2 alternating between 80 to 100 Hz) compared to sham-TENS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Midwives and the study investigator will ask parturients, who are admitted to the labor ward&#xD;
      at Region Hospital Herning satisfying the inclusion and exclusion criteria, whether they are&#xD;
      interested in attending the experimental session.&#xD;
&#xD;
      The study will be conducted as soon as the subject is admitted at the labor ward. The study&#xD;
      will only be conducted during early and active labor and not during the birth of the baby.&#xD;
&#xD;
      The subject in this study includes the package of a parturient and her neonate (after birth)&#xD;
      as we also obtain data about the neonate. Hereby, two consent forms will be obtained. As this&#xD;
      study is a non-invasive study, it is decided to have at least the consent of one parent.&#xD;
&#xD;
      The investigator will fill out a questionnaire about the parturient in cooperation with the&#xD;
      subject and midwife, including screening questions related to inclusion and exclusion&#xD;
      criteria before the experimental session starts.&#xD;
&#xD;
      The study will last approximately one hour and will be conducted during laboring&#xD;
      circumstances. KT (Kenoja Thuvarakan) will carry out the experiment, and she will be present&#xD;
      in the delivery room during the whole session.&#xD;
&#xD;
      The study includes several outcomes, including subjective and semi-objective pain measures.&#xD;
      The primary outcome is VAS (0-10 cm scale), while secondary outcomes include PPT and&#xD;
      satisfaction questionnaire (only at the end of the study). The subjects will be asked before,&#xD;
      and immediately after the experimental exposure about the four outcomes (VAS and PPT). The&#xD;
      subjects will be exposed to one of the two combinations of TENS stimulation (low and high&#xD;
      alternating frequency), which will be compared to sham-TENS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">June 6, 2021</completion_date>
  <primary_completion_date type="Actual">April 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 groups (TENS1, TENS2, and sham)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog scale (VAS)</measure>
    <time_frame>Baseline, 10 minutes post stimulation, 30 minutes post stimulation</time_frame>
    <description>10-cm pain intensity scale with 0 cm is no pain and 10 cm is unbearable pain. Decreased cm after baseline measurement indicates pain relief.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain pressure threshold</measure>
    <time_frame>Baseline, 10 minutes post stimulation, 30 minutes post stimulation</time_frame>
    <description>Pain sensitivity measurement also defined as the minimum pressure needed to evoke a pain response measured in kPa. Increased kPa after baseline measurement indicates pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of TENS</measure>
    <time_frame>Right after last measurements of VAS &amp; PPT</time_frame>
    <description>Satisfaction rating on scale from 0 to 10 [0 as 'no satisfaction' and 10 as 'total satisfaction'].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experienced pain reduction</measure>
    <time_frame>Right after last measurements of VAS &amp; PPT</time_frame>
    <description>Response to yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interest in the use of TENS again</measure>
    <time_frame>Right after last measurements of VAS &amp; PPT</time_frame>
    <description>Response to yes, no, or don't know</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recommend TENS to others</measure>
    <time_frame>Right after last measurements of VAS &amp; PPT</time_frame>
    <description>Response to yes, no, or don't know</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>TENS1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TENS2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TENS with 80/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-TENS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DS5 electrical stimulator</intervention_name>
    <description>TENS</description>
    <arm_group_label>Sham-TENS</arm_group_label>
    <arm_group_label>TENS1</arm_group_label>
    <arm_group_label>TENS2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Between ages 18-39 years&#xD;
&#xD;
          -  Vertex presentation&#xD;
&#xD;
          -  Speak, read and understand Danish&#xD;
&#xD;
          -  At term (37-42 weeks gestation age)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High-risk pregnancies (including risk factors: eclampsia, pre-eclampsia, diabetes,&#xD;
             gestational diabetes, hypertension, and hypotension, intrauterine growth restriction,&#xD;
             polyhydramnios, and oligohydramnios).&#xD;
&#xD;
          -  Pre-gestational body mass index above 40 kg/m2&#xD;
&#xD;
          -  Use of fetal-scalp electrode during the experiment&#xD;
&#xD;
          -  Use of pacemakers and other electronic implants&#xD;
&#xD;
          -  Severe arrhythmia&#xD;
&#xD;
          -  Present musculoskeletal/neurological illnesses&#xD;
&#xD;
          -  Chronic pain within last 6 months&#xD;
&#xD;
          -  Present medicated mental disorders&#xD;
&#xD;
          -  Dermatological disorders&#xD;
&#xD;
          -  Use of other long-acting pain relief&#xD;
&#xD;
          -  Use of TENS 48 hours before the trial&#xD;
&#xD;
          -  Drug addiction defines as the use of cannabis, opioids, or other drugs.&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Lack of ability to cooperate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parisa Gazerani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aalborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Region Hospital Gødstrup</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Kenoja Thuvarakan</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>TENS</keyword>
  <keyword>Labor pain</keyword>
  <keyword>Childbirth</keyword>
  <keyword>RCT</keyword>
  <keyword>Pilot study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data is described in Danish and therefore no plan of sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

